Background
Chimeric antigen receptor T-cell (CAR-T) therapy represents a promising frontier in oncology, but its application to high-grade gliomas (HGG) is challenged by the blood-brain barrier, limited efficacy, and significant toxicities associated …
Background
Liver metastases of colorectal cancer are one of the leading causes of mortality in patients with colorectal cancer. Oncolytic virus immunotherapy has demonstrated significant potential in tumor treatment; however, most oncolytic viruses ar…
Background
Cancer immunotherapy has revolutionized treatment, offering new hope for patients with previously hard-to-treat cancers. However, many solid tumors are classified as non-inflamed, meaning they are less responsive to immunotherapies. This un…
Background
The efficacy of combined chemotherapy and programmed cell death protein-1 (PD-1) immune checkpoint blockade (ICB) is constrained by the collateral cytotoxicity of chemotherapy toward proliferating tumor-specific CD8+ T (TTST) cells, a popul…
Background
Antitumor immune responses induced by oncolytic immunotherapy (OI) are often followed by upregulation of programmed death-ligand 1 (PD-L1). As such, the combination of OI with blockade of the programmed cell death protein-1 (PD-1)/PD-L1 axi…
Purpose
ASP9801, an oncolytic virus encoding interleukin-7 and interleukin-12, was assessed for safety, tolerability, pharmacokinetics, and antitumor activity in patients with advanced solid tumors in a Phase 1 study.
Methods
The study comprised Part…
Background
Prostate cancer (PCa) is a prevalent malignancy with limited treatment options for advanced stages. Oncolytic virotherapy represents a promising immunotherapeutic approach, but its efficacy and underlying mechanisms in PCa, particularly con…
Background
Nanosecond pulsed electric field (nsPEF) ablation has demonstrated limited and transient efficacy in suppressing tumor progression. Oncolytic peptide LTX-315 is known to elicit a strong antitumor immune response and durable immune memory. T…
Introduction
An adaptive immune response to cancer requires three main signals: antigen presentation and recognition (“signal 1”), costimulation (“signal 2”), and secreted immunostimulatory cytokines (“signal 3”). Expression of these signals in tumors…
Background
Cysteine–cysteine chemokine receptors 2 (CCR2) and 5 (CCR5) contribute to immune suppression in tumor microenvironments. CCR2 and CCR5 antagonists have demonstrated antitumor activity in pancreatic ductal adenocarcinoma (PDAC) and col…
